ACE2 and COVID-19: Since pre-existing chronic inflammatory conditions such as hypertension, diabetes, obesity, cardiovascular disease, as well as autoimmune diseases also activate the RAS pathway, COVID-19 patients show a significant association between ACE2 deficiency and the clinical severity of these comorbidities.